Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fosaprepitant triple antiemetic prophylaxis for prevention of postoperative nausea and vomiting after gynecologic tumor surgery
ChiCTR2200060890Phase 4Not yet recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Jun 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of fosaprepitant, palonosetron and dexamethasone in postoperative nausea and vomiting (PONV) (2 arms), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Complete response rate within 24 hours after surgery. Planned start Jun 2022; status: not yet recruiting.
02
Drugs
fosaprepitantpalonosetrondexamethasone
03
Conditions
postoperative nausea and vomiting (PONV)
Beyond the preview
Go deeper on ChiCTR2200060890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200060890.